Inovio clinches $16.17m financing:
This article was originally published in Clinica
Inovio Biomedical (San Diego, California) has secured $16.17m in the sale of common stock to institutional and accredited investors in Singapore and North America. The company, a specialist in drug delivery devices based on electroporation, sold around 4.6 million shares at $3.52 per share, in a bid to raise additional financing to fund the further development of its DNA delivery technology for gene-based therapies. The sale price represents an approximate 7% discount in comparison to Inovio's closing share price on the date of the definitive sales agreement (May 14).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.